Treace Medical Concepts EBIT

The latest EBIT for TMCI is $-56M as of June 2026. That compares with $-47M in the prior-year period — down 18.4% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Treace Medical Concepts's historical trend and sector peers before judging valuation or financial health.

Over the past year, TMCI's EBIT moved from $-47M to $-56M — a 18.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Treace Medical Concepts's operating scale or balance-sheet position.

Against Healthcare companies, TMCI currently prints $-56M for EBIT, while the sector average sits near $22B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Treace Medical Concepts's growth, margins, and balance sheet.

A EBIT figure of $-56M for TMCI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting TMCI's EBIT ($-56M), review year-over-year change from $-47M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.